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A case of zolpidem-induced hepatic
encephalopathy in a patient with major
depression
Tehmina M. Khan, Lincoln Medical and Mental Health center, NY.
Rosario Cosme PGY3, Lincoln Medical and Mental Health center, NY.
Melissa Begolli PGY3, Lincoln Medical and Mental Health center, NY.
Raj Addepalli, MD, Lincoln Medical and Mental Health center, NY.

Introduction:
This is a case report of a 49 year old man admitted to a psychiatric inpatient
unit with symptoms of severe depression, who developed hepatic
encephalopathy after being started on zolpidem.
Zolpidem is an imidazopyridine that is reported to have similar sedative
properties to the benzodiazepines but minimal effects as an anxiolytic,
muscle relaxant or anticonvulsant. It has a rapid onset, short duration of
action and is metabolized in liver through CYP450 system. Zolpidem is
extensively used as a hypnotic in short term management of insomnia. There
have been reports of hepatic encephalopathy induced by this medication.
Hepatic encephalopathy is characterized by confusion, altered level of
consciousness and potentially coma and death. It results from liver failure
and the accumulation of toxic substances in the blood stream such as
nitrogenous waste products, of which ammonia is the most commonly
measured. There is increased activity of the inhibitory gamma amino butyric
acid (GABA) system and the energy supply to other brain cells is decreased.
The diagnosis of hepatic encephalopathy is a clinical one and serum
ammonia levels are elevated in 90% of patients.

Zolpidem has shown great utility as a sleep aid in patients with major
depressive disorder, but must be approached with caution due to increasing
concerns for adverse effects on mental status. The presenting case is a report
of hepatic encephalopathy in a patient treated with zolpidem.

Case Report:
The patient is a 49 year old Hispanic man brought to the emergency
department by his wife and daughters with a chief complaint of depressed
mood and suicidal ideation. The patient presented with neurovegetative
symptoms such as poor appetite, insomnia, and decrease in psychomotor
activity, fatigue, decreased level of energy, anhedonia and passive suicidal
ideation. The patient had been having recurrent thoughts of cutting his
wrists. Evidence of psychosis or mania was absent. The patient’s history was
significant for alcohol dependence, major depressive disorder with a suicide
attempt by overdose of acetaminophen several months prior to this
admission. The patient also has a past medical history of hepatitis C, with
cirrhosis, HIV, asthma, hypertension and stroke.
Upon admission to the inpatient psychiatric unit, the patient was started on
sertraline 50mg daily which was not tolerated due to the emergence of
gastrointestinal side effects. The patient was then placed on bupropion
150mg oral daily which was titrated to 300mg oral daily with considerable
improvement in mood. However the patient continued to have poor sleep
for which he was started on zolpidem at a dose of up to ten milligrams. After
the initiation of zolpidem, the patient became progressively more isolative
and refused to eat or take his medications. He became increasingly paranoid,
irritable and then his mental status worsened revealing confusion and
disorientation that exacerbated to the point of being unable to recognize his
family members.
Zolpidem was discontinued. His ammonia level on admission was 49mg/dl.
After initiation of zolpidem, his ammonia level increased up to 141mg/dl
and then decreased back to 36mg/dl four days after the discontinuation of
zolpidem with improvement of patient’s symptoms.

Discussion:
In this case, there is evidence of worsening of mental status in a 49 year old
man after treatment with zolpidem. In a small number of previous reports,
the encephalopathy is caused directly by acute liver failure. More
commonly, especially in chronic liver disease, hepatic encephalopathy is
caused or aggravated by additional causes (excessive nitrogen load,
electrolyte or metabolic disturbances, infections, drugs and medications like
benzodiazepines and alcohol). Identifying these causes can be important to
treat the episode effectively. Benzodiazepines are generally avoided in
patients with advanced liver disease because they mediate GABAergic
neurotransmission. Although zolpidem in theory has the same propensity to
induce hepatic encephalopathy, its shorter half- life has made it a reasonable
choice for subjects with chronic liver disease. However, increasing evidence
of encephalopathy induced by zolpidem has been reported, (1, 2). In some
cases, Flumazenil has been used to reverse the excessive confusion in such
patients who were given zolpidem and good results were seen, (1).
Zolpidem is metabolized hepatically and excreted as a metabolite in urine,
bile and feces. Plasma protein binding of zolpidem is markedly decreased in
the presence of hepatic impairment and exacerbated by concomitant use of
other medications that may displace zolpidem from carrier proteins.
Therefore we recommend that clinicians should cautiously prescribe
zolpidem keeping such factors in mind so as to minimize its side effects.
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